Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model
Nimacimab shows comparable weight loss to monlunabant and tirzepatide alone, and an additive effect in combination with tirzepatide, in diet-induced obesity model
New data demonstrates superior potency of nimacimab's differentiated and favorable mechanism of inhibition versus monlunabant
Nimacimab Phase 2a CBeyond™ top-line randomized data expected late Q3/early Q4 2025
SAN DIEGO, April 15, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ('Skye'), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced new preclinical data for its novel CB1 antibody, nimacimab. In a murine diet-induced obesity (DIO) model, after 25 days of treatment, results demonstrated:
Greater than 30% weight loss when nimacimab was combined with the dual GLP-1/GIP agonist, tirzepatide
Nimacimab alone demonstrated 23.5% weight loss, comparable to monlunabant and tirzepatide alone.
'This new preclinical study highlights that a truly peripherally-restricted CB1 inhibitor—nimacimab—effectively drives weight loss in a DIO model. Nimacimab compared favorably to and provided significant additive weight loss when combined with GLP-1-targeted drugs like tirzepatide,' said Punit Dhillon, CEO of Skye. 'Using higher doses, this study builds on our previous preclinical DIO data in human CB1 knock-in mice that showed significant dose-dependent weight loss. Biomarker analyses demonstrated that nimacimab-driven weight loss was associated with beneficial changes in key hormones, glycemic control, and inflammatory markers.
'Skye believes nimacimab shows potential both as a monotherapy and in combination with a GLP-1 targeted drug to address unmet needs in obesity with the potential to change weight loss standards of care. Initial data from Skye's Phase 2a study in obesity is expected in late Q3/early Q4 2025.'
Mr. Dhillon added, 'The second key finding of this animal study is that Skye's highly-peripherally restricted nimacimab drives efficacy similar to a less-peripherally restricted CB1 inhibitor, monlunabant, in a DIO model. These in vivo data continue to support our belief that our differentiated antibody approach can potentially provide meaningful efficacy without the challenge current small molecule CB1 inhibitors face—brain exposure that can cause unwanted neuropsychiatric side effects.'
Figure 1 - DIO model to interrogate combination of nimacimab and tirzepatideNew In Vitro Data Characterizes Differentiated Potency Characteristics
Skye also shared new in vitro potency data demonstrating that nimacimab's non-competitive allosteric binding to CB1 provides for a differentiated and potentially advantageous mechanism of inhibition versus small molecules like monlunabant, which must compete with CB1 agonists. In this study, potency of nimacimab and monlunabant were assessed against two concentrations of the CB1 agonist CP55940. The first condition evaluated potency of each drug with a lower concentration of CP55940 (50nM or EC80), while the second condition evaluated potency against an elevated concentration of CP55940 (2000nM or 40X EC80). These two conditions serve as a model of a physiological versus a pathological state where conditions such as obesity can promote an increase in the CB1 ligands, anandamide (AEA) and 2-arachidonoylglycerol (2-AG), and thus competition for the CB1 receptor. These data demonstrated that while nimacimab's potency remained relatively stable, the activity of monlunabant when challenged with a higher concentration of a CB1 agonist was significantly impacted.
Dr. Chris Twitty, Chief Scientific Officer of Skye, said, 'These data demonstrate for the first time how nimacimab's allosteric binding to the CB1 receptor is differentiated from the small molecules which bind to the receptor's active orthosteric site. We know that in a disease state such as obesity, the CB1 receptor as well as its natural ligands, AEA and 2-AG, are upregulated. In this diseased state, there may be significant competition for the active binding site. In our in vitro experiment we aimed to recreate this potential situation. The biological impact of these data suggests that when there is significant competition for CB1 binding, the activity of small molecules like monlunabant can be significantly impacted. Clinically this could result in impacting the relationship between pharmacodynamics and pharmacokinetics of the drug, ultimately requiring more of the small molecule to overcome the competition. Alternatively, nimacimab does not compete for the same site as the natural ligands, and our data show that as a result of this allosteric binding, the potency is minimally impacted regardless of the concentration of competing molecules.'
'In the context of CB1 inhibition, we aim to realize the weight loss and metabolic benefits of this mechanism without the neuropsychiatric side effects seen with small molecule drugs. In our estimation, the potential of superior potency of nimacimab in this disease state may offer the widest possible therapeutic window among CB1 inhibitors.'
Figure 2 - Comparison of potency between monlunabant* and nimacimab*** Monlunabant's potency dropped significantly at high agonist levels due to direct competition for the receptor's orthosteric site.** Nimacimab's potency was preserved due to its allosteric binding mechanism that avoids direct competition.
About Skye Bioscience
Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: www.skyebioscience.com. Connect with us on X and LinkedIn.
CONTACTSInvestor Relationsir@skyebioscience.com(858) 410-0266
LifeSci Advisors, Mike Moyermmoyer@lifesciadvisors.com(617) 308-4306
Media InquiriesLifeSci Communications, Michael Fitzhughmfitzhugh@lifescicomms.com(628) 234-3889
FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, forward-looking statements can be identified by terminology including 'anticipated,' 'plans,' 'goal,' 'focus,' 'aims,' 'intends,' 'believes,' 'can,' 'could,' 'challenge,' 'predictable,' 'will,' 'would,' 'may' or the negative of these terms or other comparable terminology. These forward looking statements include, but are not limited to: (i) statements regarding the superior safety and tolerability profile of nimacimab relative to other small molecule CB1 inhibitors, (ii) statements relating to any expectations regarding the efficacy and therapeutic potential of nimacimab as a monotherapy or in combination with a GLP-1 targeted drug, including expectations based on preclinical DIO models, (iii) statements regarding nimacimab's potential to change weight loss standards of care, (iv) statements regarding superior potency of nimacimab to other small molecule CB1 inhibitors based on nimacimab's mechanism of action and (v) statements regarding the timing of receipt of final data from Skye's Phase 2 obesity study of nimacimab. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Company's periodic filings with the Securities and Exchange Commission, including in the 'Risk Factors' section of Skye's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/97a10bc7-3e79-4fbc-9275-d0929f35c403
https://www.globenewswire.com/NewsRoom/AttachmentNg/acfb12e0-c08e-4700-b340-bc19d8a8a712
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Upturn
26 minutes ago
- Business Upturn
Bitget Scans Ahead at Solana Summit 2025 with QR-based Payment Rollout
VICTORIA, Seychelles, June 10, 2025 (GLOBE NEWSWIRE) — Bitget Wallet, the leading non-custodial Web3 wallet, concluded an impactful showing at the Solana APAC Summit 2025, held in Da Nang, Vietnam from June 5 to 7. As a major sponsor of the summit, Bitget Wallet used the three-day event to debut its newest payment features, connect with builders from across the Solana ecosystem, and demonstrate how onchain tools can power real-world use cases across Asia and beyond. On the opening day, Bitget Wallet formally announced the integration of QR-based payment integrations, which includes Solana Pay and national QR payment systems, for seamless, multi-currency payments. This integration lives up to Bitget Wallet's new identity of 'Crypto for Everyone', bridging the gap between blockchain and everyday commerce. Bitget Wallet also hosted a developer workshop showcasing the ease of integrating Solana dApps into the wallet's infrastructure, including support for seamless swaps, staking, and native Solana trading via Jupiter DEX. Day 2 of the Summit saw Bitget Wallet's Business Development Manager, Xavier Ow Yeong, take the stage to discuss how onchain finance is changing the way users spend, save, and access capital. That evening, Bitget Wallet co-hosted a meetup with Saros, previewing its upcoming VietQR payment feature in a live test environment. Over 150 community members attended the event, explored new Bitget Wallet integrations firsthand, and received exclusive merchandise alongside a live airdrop reward for early testers. The Solana APAC Summit marks a significant milestone in Bitget Wallet's roadmap to turn crypto wallets from storage tools into everyday super apps. As part of a broader mission to scale real-world adoption, the event demonstrates how embedded payment infrastructure, cross-chain liquidity, and user-first design can unlock new crypto behaviors, whether in emerging markets or global hubs of Web3 development. Bitget Wallet's participation in the Solana Summit is part of its ongoing initiative to expand crypto access across Asia, aligning ecosystem partners, developers, and communities around the next wave of practical, onchain tools. About Bitget WalletBitget Wallet is a non-custodial crypto wallet designed to make crypto simple and secure for everyone. With over 80 million users, it brings together a full suite of crypto services, including swaps, market insights, staking, rewards, DApp exploration, and payment solutions. Supporting 130+ blockchains and millions of tokens, Bitget Wallet enables seamless multi-chain trading across hundreds of DEXs and cross-chain bridges. Backed by a $300+ million user protection fund, it ensures the highest level of security for users' assets. Its vision is Crypto for Everyone — to make crypto simpler, safer, and part of everyday life for a billion more information, visit: X | Telegram | Instagram | YouTube | LinkedIn | TikTok | Discord | Facebook For media inquiries, contact [email protected]


Business Upturn
26 minutes ago
- Business Upturn
Online Tax Firm MyExpatTaxes Alerts Expats: Final Chance to Claim 2021 Stimulus Payments
Vienna, June 10, 2025 (GLOBE NEWSWIRE) — MyExpatTaxes, a leading US expat tax company known for its support of U.S. citizens living overseas, is highlighting an important upcoming deadline for American expatriates. By June 16th, expats must act to claim the 2021 stimulus payments. This deadline represents the final opportunity for expats who haven't already to benefit from COVID-19 economic stimulus payments, which can total thousands of . MyExpatTaxes is urging individuals not to miss out on this opportunity. As the U.S. is one of just two countries that taxes based on citizenship rather than residence, Americans living abroad have to report their worldwide income by filing a U.S. tax return every year. Many Americans expats are unaware of this requirement to file from overseas though, so get behind in their filing. The IRS has an amnesty program for these expats though called the Offshire Streamlined Filing Compliance Procedures. This process offers a chance for overseas Americans who have unintentionally failed to meet their filing obligations to catch up on their U.S. tax filing without facing penalties. It requires submitting the last three years of tax returns and, where applicable, up to six years of Foreign Bank and Financial Accounts Reports (FBARs). The procedure can seem complex, but with MyExpatTaxes offering either self-service or guided assistance, expats can find a sense of relief with easy access to tools like a US expat tax calculator and a stimulus check calculator found on their website. Nathalie Goldstein, CEO of MyExpatTaxes, underscores the significance of acting before the June 16th deadline for non-compliance overseas Americans, saying, 'The June 16th 2025 deadline is the last opportunity for American expatriates who may not have been aware that they have to file U.S. taxes from abroad to claim teh COVID-19 stimulus payments. It's also a valuable opportunity to get tax compliant without facing penalties. Our goal is to provide them with the guidance they need to make the most of these benefits.' Her words reflect the broader mission of MyExpatTaxes – supporting American expats in navigating what can often be a daunting process filing from overseas (often as well as filing taxes in the country where they reside). The 2021 expanded Child Tax Credit is also available for American families living abroad. This credit offers a substantial benefit of up to $3,600 per child, refundable for qualifying families. Timely filing is critical to claim this credit, ensuring families don't inadvertently miss out. To aid in this, expats can access comprehensive guidance and information on the Streamlined Procedures through MyExpatTaxes' dedicated page: Adding to the firm's efforts, Goldstein remarks, 'The potential gains for catching up and filing for 2021 for expats who qualify for the stimulus payments are typically far outweigh the costs of becoming compliant. Our platform is designed to simplify the tax filing process for U.S. citizens abroad, offering practical solutions and expert support. With the deadline imminent to claim these valuable payments, we're dedicated to helping expatriates claim what they are rightfully owed.' This statement emphasizes MyExpatTaxes' commitment to easing the stress associated with U.S. tax filing for expats. To further assist expats, the company has developed easy-to-use resources such as tax guides, quick start checklists, and webinars available on their website. These resources provide education and support, aimed at simplifying and demystifying the intricacies of international tax reporting for Americans living abroad. User testimonials and official reviews highlight the effectiveness and reliability of MyExpatTaxes' services, reinforcing their reputation as a helpful aid for expats. As the June 16th deadline approaches, expats need to be vigilant. Missing this date means losing out on the chance to claim the stimulus payments for good. Through proactive action and using MyExpatTaxes' offerings, expatriates can not only ensure compliance but also capitalize on available benefits. MyExpatTaxes remains committed to guiding expatriates through these important periods, helping them understand and fulfill their tax responsibilities while maximizing their eligible claims. For those seeking to learn more or benefit from these services, they can learn more through the platform's site: The resources provided are not just about fulfilling obligations – they also empower expats to take control of their financial responsibilities with confidence. ### For more information about MyExpatTaxes, contact the company here: MyExpatTaxesMackenzie Passegger [email protected]


Business Upturn
26 minutes ago
- Business Upturn
SEON Launches AI-Powered Anti-Money Laundering Suite, Enhancing its Comprehensive Command Center for Risk Management
AUSTIN, Texas, June 10, 2025 (GLOBE NEWSWIRE) — SEON , a global leader in digital fraud prevention , announced the launch of its expanded Anti-Money Laundering (AML) Compliance suite, a significant step in the company's evolution from fraud prevention to a unified risk solution. This release introduces real-time AI-powered capabilities, including Payment Screening , Transaction Monitoring and integrated fraud and AML Case Management with regulatory reporting filling functionalities. SEON's 2025 Digital Fraud Outlook reveals real-time transaction monitoring is the top investment priority for compliance and fraud teams this year — with 62% of organizations making this shift. To meet this demand, SEON's AML suite delivers granular, real-time monitoring alerts that reduce false positives and improve detection accuracy across both fraud and AML use cases. 'We already use SEON as a key part of how we manage fraud risk at Casumo,' said Sebastian Brant, Director of CEX, Casumo. 'They bring depth in proprietary risk signals we can't get anywhere else, flexible tools that we can adapt to any scenario and a level of customer service responsiveness and expertise we simply haven't seen elsewhere. We see the significant value of having one system that can help teams operate more efficiently and effectively.' SEON serves as the unified solution for teams managing both fraud and AML compliance, helping them detect risks proactively, resolve cases faster and keep records audit-ready — all without navigating between different systems, eliminating manual steps or working off spreadsheets. 'Risk teams don't need more tools — they need one that gives them a full picture,' said Tamas Kadar, Co-Founder and CEO, SEON. 'This launch gives fraud and compliance teams a multi-dimensional command center to manage risk in one place. And because we own our data pipeline and can control data accuracy, this means our models deliver more accurate risk decisions.' Built for the Way Risk and Compliance Work Today Most risk teams are using legacy solutions that were not designed to support real-time decisions, instead relying on batch processing, leading to delayed reviews, siloed data and scattered case files with no audit trail. SEON replaces that with a single solution where fraud and AML data work together — giving teams a holistic view with more context, less noise and quicker paths to action. Developed through customer collaboration, SEON's AML Compliance solution applies the same real-time capabilities, data quality and limitless customization that SEON is known for to compliance use cases, helping teams tailor risk programs to new products, regulatory jurisdictions, internal policies and evolving risks. Key Capabilities Spot bad actors early with digital footprint and fraud signals before users enter KYC or AML checks with digital footprint and fraud signals before users enter KYC or AML checks Expedite reviews with AI-assisted customer screening that helps analysts resolve hits faster with AI-assisted customer screening that helps analysts resolve hits faster Detect risks instantly with real-time transaction monitoring and payment screening with real-time transaction monitoring and payment screening Investigate efficiently and close out cases faster with unified fraud intelligence, AML signals and transaction data in one dashboard and close out cases faster with unified fraud intelligence, AML signals and transaction data in one dashboard Reduce time spent on regulatory reporting with autofill capabilities and AI-powered SAR narratives with autofill capabilities and AI-powered SAR narratives Submit SAR, CTR, and Form 8300 reports to FinCEN in one click, with status tracking and audit history; with expansion in progress to other regulatory bodies in one click, with status tracking and audit history; with expansion in progress to other regulatory bodies Lean on expert support from SEON's Managed Risk Services team, offering guidance and rule management for leaner teams About SEON SEON helps risk teams detect and stop fraud and money laundering while ensuring regulatory compliance. By combining real-time digital footprint analysis , device intelligence and AI-driven rules , SEON empowers thousands of businesses globally to prevent threats before they occur. With integrated fraud prevention and AML capabilities, SEON operates from Austin, London, Budapest and Singapore. Learn more at . Media [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.